Publications by authors named "N A Compagnone"
Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant disorder characterized by progressive muscle weakness. Adenine nucleotide translocator 1 (ANT1), the only 4q35 gene involved in mitochondrial function, is strongly expressed in FSHD skeletal muscle biopsies. However, its role in FSHD is unclear.
View Article and Find Full Text PDFPurpose: Morphometric vertebral fractures (VFs) have been recently reported as an important component of the endocrine phenotype of COVID-19 and emerging data show negative respiratory sequelae at long-term follow-up in COVID-19 survivors. The aim of this study was to evaluate the impact of VFs on respiratory function in COVID-19 survivors.
Methods: We included patients referred to our Hospital Emergency Department and re-evaluated during follow-up.
Article Synopsis
- This study assessed the respiratory issues faced by COVID-19 survivors six months post-hospital discharge, finding that 37.3% had some form of respiratory dysfunction.
- A logistic regression model was created to predict these issues based on factors like sex, obesity, and previous oxygen levels during admission.
- The model showed 73% accuracy in identifying at-risk patients, outperforming simpler models that only considered initial oxygen levels.
Residual lung damage following ARDS in COVID-19 ICU survivors.
Acta Anaesthesiol Scand
February 2022
Background: Coronavirus disease 2019 acute respiratory distress syndrome (COVID-19 ARDS) is a disease that often requires invasive ventilation. Little is known about COVID-19 ARDS sequelae. We assessed the mid-term lung status of COVID-19 survivors and investigated factors associated with pulmonary sequelae.
View Article and Find Full Text PDFBackground: Coronavirus disease 2019 (COVID-19) may leave behind an altered health status early after recovery. We evaluated the clinical status of COVID-19 survivors at three months after hospital discharge.
Methods: In this prospective observational cohort study, hospitalized patients aged ≥18 years, evaluated at one (M1) and three (M3) months post-discharge were enrolled.